US FDA warns CBD firms over inadequate testing, labelling and health claims

The US Food and Drug Administration (FDA) has told two CBD companies they fell short of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and ordered them to undertake proper testing ...

Restricted content. Do you want to read more?